Literature DB >> 17245764

Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.

Carlos Eduardo Coral de Oliveira1, Gabriela Gonçalves de Oliveira Cavassin, Aparecida de Lourdes Perim, Thiago Franco Nasser, Karen Brajão de Oliveira, Maria Helena Pelegrinelli Fungaro, Juliana Laino do Val Carneiro, Maria Angelica Ehara Watanabe.   

Abstract

Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disorder that originates from a pluripotent stem cell expressing the bcr-abl oncogene. It is characterized by an abnormal release of the expanded, malignant stem cell clone from the bone marrow into the circulation. The stromal cell derived factor-1 (SDF-1) gene contains a common polymorphism, termed SDF1-3'A, in an evolutionarily conserved segment of the 3' untranslated region (UTR). In this work the SDF-1 genotypes of 25 patients (9-82 years old) who had been clinically and hematologically diagnosed with CML were compared with those of 60 healthy donors. In addition, the nature of bcr-abl hybrid mRNA and the association between demographic and hematological parameters were analyzed in cells from 12 CML patients (five women and seven men). All patients underwent blood collection during the chronic phase of disease after they received chemotherapy. b3a2 mRNA was detected in samples from eight of the CML patients and b2a2 mRNA was observed in four cases. An association between basophils and hemoglobin parameters was observed in that hemoglobin levels were higher in b2a2-expressing patients, and mean basophil levels were higher in patients expressing b3a2. Four of the CML patients (16%) were homozygous for 3'A allele. Of the patients who showed the presence of bcr-abl transcripts (N = 12), three presented the wt/wt genotype and nine were SDF1-3'A carriers. Three of the latter were homozygous for this mutation. It is possible that the bcr-abl fusion gene and the SDF1 genotype for 3'A allele have important implications for the pathogenesis of CML. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245764      PMCID: PMC6649230          DOI: 10.1002/jcla.20142

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  24 in total

1.  Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

Authors:  J A Burger; M Burger; T J Kipps
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

2.  Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1.

Authors:  Amnon Peled; Izhar Hardan; Luba Trakhtenbrot; Eyal Gur; Michal Magid; Merav Darash-Yahana; Ninette Cohen; Valentin Grabovsky; Suzana Franitza; Orit Kollet; Ofer Lider; Ronen Alon; Gideon Rechavi; Tsvee Lapidot
Journal:  Stem Cells       Date:  2002       Impact factor: 6.277

3.  Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival.

Authors:  P Shepherd; R Suffolk; J Halsey; N Allan
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

Review 4.  Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?

Authors:  A Zaccaria; G Martinelli; N Testoni; E Zuffa; P Farabegoli; D Russo; A Guerrasio; S Tura
Journal:  Leuk Lymphoma       Date:  1995-01

5.  Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins.

Authors:  K Tashiro; H Tada; R Heilker; M Shirozu; T Nakano; T Honjo
Journal:  Science       Date:  1993-07-30       Impact factor: 47.728

6.  p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.

Authors:  Jean-Francois Geay; Dorothée Buet; Yanyan Zhang; Adlen Foudi; Peggy Jarrier; Magali Berthebaud; Ali G Turhan; William Vainchenker; Fawzia Louache
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

Review 7.  Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.

Authors:  J L Fernandez-Luna
Journal:  Apoptosis       Date:  2000-10       Impact factor: 4.677

8.  New tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  Giovanni Martinelli; Simona Soverini; Gianantonio Rosti; Daniela Cilloni; Michele Baccarani
Journal:  Haematologica       Date:  2005-04       Impact factor: 9.941

9.  [Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia].

Authors:  Alejandro Rosas-Cabral; Manuel Martínez-Mancilla; Manuel Ayala-Sánchez; Jorge Vela-Ojeda; Patricia Bahena-Reséndiz; Manuel Vadillo-Buenfil; J Antonio Aviña-Zubieta; Daniel Salazar-Exaire; Enrique Miranda-Peralta; Alberto Marroquín; Ernesto Longoria-Revilla
Journal:  Gac Med Mex       Date:  2003 Nov-Dec       Impact factor: 0.302

10.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)

Authors:  C C Bleul; R C Fuhlbrigge; J M Casasnovas; A Aiuti; T A Springer
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  14 in total

1.  CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2012-06-15       Impact factor: 3.984

2.  CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL).

Authors:  Aparecida de Lourdes Perim; Roberta Losi Guembarovski; Julie Massayo Maeda Oda; Leandra Fiori Lopes; Carolina Batista Ariza; Marla Karine Amarante; Maria Helena Pelegrinelli Fungaro; Karen Brajão de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Mol Biol Rep       Date:  2013-05-08       Impact factor: 2.316

3.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

4.  Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population.

Authors:  Vibha Singh; Praveen Kumar Jaiswal; Rohit Kapoor; Rakesh Kapoor; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-01-16

5.  Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors.

Authors:  Beatriz Martín-Antonio; Magdalena Carmona; Jose Falantes; Encarnación Gil; Alicia Baez; María Suarez; Pedro Marín; Ildefonso Espigado; Alvaro Urbano-Ispizua
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

Review 6.  CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

Authors:  Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

7.  Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia.

Authors:  Mustafa Pehlivan; Handan Haydaroglu Sahin; Sacide Pehlivan; Kursat Ozdilli; Leylagul Kaynar; Fatma Savran Oguz; Tugce Sever; Mehmet Yilmaz; Bulent Eser; Yeliz Duvarci Ogret; Cem Kis; Vahap Okan; Mustafa Cetin; Mahmut Carin
Journal:  Genet Test Mol Biomarkers       Date:  2014-05-12

8.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  SDF1 gene variation is associated with circulating SDF1alpha level and endothelial progenitor cell number: the Bruneck Study.

Authors:  Qingzhong Xiao; Shu Ye; Friedrich Oberhollenzer; Agnes Mayr; Marjan Jahangiri; Johann Willeit; Stefan Kiechl; Qingbo Xu
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

10.  Silencing HIF-1α reduces the adhesion and secretion functions of acute leukemia hBMSCs.

Authors:  Zeng Dong-Feng; Liu Ting; Chang Cheng; Zhang Xi; Liang Xue; Chen Xing-Hua; Kong Pei-Yan
Journal:  Braz J Med Biol Res       Date:  2012-10       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.